Researchers at the University of Queensland, working with international partners, have announced a significant advance in understanding and potentially treating Motor Neurone Disease (MND).

The team developed a novel drug molecule called R8Y that selectively binds to a difficult-to-target immune receptor known as C5aR2, found on many immune cells.

By using this compound, scientists were able to map the receptor’s structure and uncover unusual biological behavior, including the discovery that C5aR2 does not couple to G proteins like most similar receptors, explaining why it has been difficult to target in past drug development efforts.

The research was conducted in collaboration with institutions including the Indian Institute of Technology, the University of Tokyo, and Sungkyunkwan University, highlighting the global effort behind the discovery.

The findings provide a new molecular tool that allows scientists to study inflammatory pathways more precisely and may open the door to safer and more effective anti-inflammatory therapies.

According to researchers, this breakthrough could accelerate the development of treatments not only for MND but also for other neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.The University of Queensland team is now using this knowledge to design improved drugs aimed at modulating inflammation in the nervous system.

Importantly, researchers have suggested that if development continues successfully, early-stage clinical testing in MND patients could potentially begin within five years, offering hope that the disease might eventually be managed as a chronic condition rather than an immediately fatal one.

The project received funding support from the FightMND foundation and the National Health and Medical Research Council, reflecting strong institutional backing for ongoing neurodegenerative disease research.